Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

TRX E 002 1

Drug Profile

TRX E 002 1

Alternative Names: Cantrixil; TRX-E-002-1; TRX1; TRXE002

Latest Information Update: 27 Oct 2023

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Novogen
  • Developer Kazia Therapeutics
  • Class Antineoplastics; Benzopyrans; Small molecules
  • Mechanism of Action Electron transport chain complex protein inhibitors; Tubulin polymerisation inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Ovarian cancer
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Ovarian cancer
  • No development reported Fallopian tube cancer; Peritoneal cancer

Most Recent Events

  • 25 Oct 2023 TRX E 002 1 is still in phase-I development for Ovarian-cancer(Monotherapy, Combination therapy, Second-line therapy or greater) in USA and Australia (Intraperitoneal) (Vivesto pipeline, October 2023)
  • 28 Apr 2022 No recent reports of development identified for phase-I development in Fallopian-tube-cancer(Combination therapy, Second-line therapy or greater) in Australia (Intraperitoneal)
  • 28 Apr 2022 No recent reports of development identified for phase-I development in Fallopian-tube-cancer(Combination therapy, Second-line therapy or greater) in USA (Intraperitoneal)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top